The study, led by J. F. Trujillo-Rivera and M. Gutiérrez-Valencia with senior author N. Martínez-Velilla and colleagues based at Navarrabiomed and the Hospital Universitario de Navarra in Pamplona, Spain, revisited data from a randomized clinical trial registered as NCT02300896. The original trial had enrolled 310 acutely hospitalized patients aged over 75, with an average age of 87 and a majority of women at 58.7 percent of the sample. Participants were assigned either to a supervised multicomponent exercise program delivered during their hospital admission or to standard hospital care. The team behind the new analysis asked a deceptively simple question: does taking a statin change how much a very old, acutely ill patient gains from exercise?

The question matters because statins occupy an ambivalent place in geriatric medicine. On one hand, these HMG-CoA reductase inhibitors are among the most widely prescribed drugs in the world, valued for cardiovascular prevention and increasingly discussed for so-called pleiotropic effects on inflammation, oxidative stress and immunomodulation. On the other hand, statins have long carried a reputation for muscle-related side effects, ranging from myalgia to, rarely, rhabdomyolysis, and some observational studies have linked statin use to lower physical activity, reduced exercise capacity and weaker physical performance in older people. If statins truly blunted the muscle’s adaptive response to training, prescribing them to frail elders who need every gram of muscle they can keep would be a genuine clinical dilemma.

Previous research had hinted at a more optimistic picture. A 2012 study in Age Ageing found that older people on statins showed better outcomes during inpatient rehabilitation, and a 2018 trial in dyslipidemic older adults reported that combining statin therapy with exercise training improved functional status more than exercise alone. Mechanistic work in animal and human muscle has suggested that statins and exercise may interact in complex ways, with some evidence of attenuated mitochondrial responses in certain contexts and other evidence of anti-inflammatory benefits that could support recovery. The heterogeneity of these findings was a central theme of a 2023 National Institutes of Health workshop on optimizing exercise responses in older adults, which called for better understanding of why individuals differ in how they respond to training. The new Spanish analysis speaks directly to that agenda in one of the most vulnerable populations imaginable: patients in the middle of an acute hospital admission.

The primary outcome of the analysis was the change in the Barthel Index, a widely used measure of independence in activities of daily living that scores functions such as feeding, bathing, dressing, continence, toileting, transferring, mobility and stair climbing. The index is particularly meaningful in geriatric hospital care because it captures the practical abilities that determine whether a patient can return home or will need institutional support. Prior work in stroke patients has established thresholds for the minimal clinically important difference of the Barthel Index, giving clinicians a benchmark for judging whether a measured change is large enough to matter in daily life rather than merely registering as a statistical blip.

The headline result is reassuringly straightforward: exercise worked, and it worked regardless of statin use. Patients who received the supervised multicomponent program improved their functional outcomes, and this benefit was observed across the cohort whether or not they happened to be taking a statin. In other words, the fundamental message of the original trial, that very old hospitalized patients can and should be exercised even during acute illness, survives the stratification by lipid-lowering therapy. For clinicians who have hesitated to enroll statin users in ward-based exercise programs for fear of provoking muscle damage, the safety data are equally welcome: the researchers observed no statin-related adverse muscle events during the intervention.

Beneath that main finding, however, sits a more provocative one. In exploratory adjusted models, statin users showed a potentially greater improvement in Barthel Index scores than non-users, with a mean difference of 5.58 points and a 95 percent confidence interval of 0.44 to 10.7, yielding a p value of 0.035. The authors themselves are careful to flag that this finding should be interpreted with caution, and the caution is warranted on several grounds. The analysis was secondary and exploratory rather than designed and powered to test the statin question, so the comparison of statin users to non-users is observational in nature even though it sits inside a randomized trial. Patients on statins may differ systematically from those who are not, in cardiovascular burden, in frailty trajectories, in the medications they take alongside them, and in the very reasons they were admitted to hospital. Any of these differences could bias the apparent effect in either direction.

Still, the size of the signal is worth pausing on. A 5.58-point difference on the Barthel Index approaches or exceeds the minimal clinically important difference reported in some patient populations, which would mean the gap is not just statistically detectable but potentially meaningful at the bedside, translating into a patient who can dress independently or walk to the bathroom without help. The confidence interval, while it includes values close to zero, also extends to nearly 11 points, so the data are compatible with effects ranging from trivial to substantial. If the signal is real, plausible biological mechanisms exist to explain it: statins’ anti-inflammatory and antioxidant actions could dampen the catabolic storm of acute illness, their immunomodulatory properties might speed recovery, and emerging research on statins and sarcopenia has explored whether the drugs influence muscle mass and function in aging. The hospital setting, where inflammation and immobilization conspire to strip away function, could theoretically be where such pleiotropic effects are most visible.

The authors are explicit about the practical takeaway, and it is one that resists overinterpretation. Exercise interventions confer functional benefits during acute hospitalization regardless of statin use, they conclude, and the results reinforce the safety of maintaining statins in acutely ill older adults while supporting the implementation of exercise programs on the ward. That framing deliberately avoids recommending statins as an exercise enhancer, a claim the data cannot support. What the study does support is a de-prescribing question answered in the negative: there is no evidence here that continuing a statin during hospitalization undermines a patient’s ability to benefit from rehabilitation, and no evidence that statin users need to be protected from physical activity. In a field where medications are frequently stopped on admission out of generalized caution, that is a consequential null result wrapped around an intriguing positive one.

The broader significance lies in the growing science of response heterogeneity. As the NIH workshop summary and a wave of recent reviews have emphasized, the average treatment effect reported in a trial can conceal enormous individual variation, and modifiers such as coexisting medications, baseline fitness and disease burden determine who benefits most. This analysis is a template for that line of inquiry: take a completed randomized trial with a hard functional endpoint, stratify by a common, modifiable co-treatment, and report both the reassuring main effect and the exploratory interaction with appropriate humility. Whether statins genuinely amplify the functional dividends of ward-based exercise will require dedicated randomized studies designed for that question, ideally with muscle-specific outcomes such as strength, mass and mitochondrial function layered alongside the Barthel Index. Until then, the message for the growing population of very old hospital patients is refreshingly simple: keep moving, keep taking the pills your doctor has judged worthwhile, and expect the exercise to work either way.

Subject of Research: The interaction between statin use and functional response to multicomponent exercise in acutely hospitalized older adults

Article Title: Statin use and functional response to multicomponent exercise in acutely hospitalized older adults: secondary analysis of a randomized trial

Article References: Trujillo-Rivera, J. F., Gutiérrez-Valencia, M., Galbete, A., Chenhuichen, C., Zambom-Ferraresi, F., & Martínez-Velilla, N. (2026). Statin use and functional response to multicomponent exercise in acutely hospitalized older adults: secondary analysis of a randomized trial. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01615-7

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01615-7

Keywords: statins, exercise therapy, hospitalization, older adults, Barthel Index, functional decline, geriatrics, randomized controlled trial, sarcopenia, physical performance, acute care, rehabilitation

High-flow nasal cannula is a deceptively simple piece of technology. Instead of a mask covering the nose and mouth, heated, fully humidified gas is delivered through a wide-bore nasal interface at flow rates of up to 60 liters per minute, with the fraction of inspired oxygen adjusted to the patient’s needs. The therapy provides several physiological advantages: it generates low levels of positive airway pressure, flushes carbon dioxide out of the upper airway’s anatomical dead space, reduces the work of breathing, and improves clearance of secretions. Because it leaves the mouth free, patients can talk, eat, and drink while receiving support, and the open nasal interface dramatically reduces the claustrophobia and skin breakdown that plague mask users. Evidence in other neuromuscular diseases has hinted that patients tolerate it better than conventional ventilation, but data specific to ALS have been scarce, largely confined to small observational studies from high-income tertiary centers at moderate altitudes.

The new study, conducted by a multidisciplinary home respiratory care team, followed 18 ALS patients enrolled between January 2014 and December 2024 in a specialized home care program for neuromuscular disease. All had confirmed ALS, evidence of chronic respiratory failure, and clinician-documented intolerance to non-invasive ventilation attributable to interface problems, claustrophobia, excessive secretions, dysphagia, behavioral intolerance, or anatomical obstacles. The researchers combed electronic medical records for demographic details, comorbidities, arterial blood gas measurements, respiratory muscle strength, functional status, hospitalizations, infections, and mortality, comparing outcomes at the start of high-flow therapy with the last available follow-up.

The cohort tells its own story about how relentlessly ALS advances. The average age at which high-flow nasal cannula was initiated was 65.1 years, roughly eight years after the average age at diagnosis of 57.5. Women made up two-thirds of the group, and the mean body mass index was 23.6 kilograms per square meter. Notably, 61 percent of patients also carried a diagnosis of obstructive sleep apnea, a comorbidity that may compound ventilatory vulnerability. Comorbidities otherwise were sparse: four patients had hypertension, one had diabetes, and none had cancer, thrombotic disease, or autoimmune conditions beyond a single case of rheumatoid arthritis. These are, in other words, patients whose respiratory failure was driven by ALS itself rather than by a burden of other illness.

The pattern of intolerance to masks was revealing. In seven of the 18 cases, intolerance was partial, rooted in difficulty adapting to the interface, claustrophobic sensations, or discomfort with the delivered airflow. Six patients, about a third of the cohort, managed short periods of mask ventilation alternating with high-flow support, using the cannula for an average of about 4.7 hours daily. During the observation period, half of the patients required at least one hospitalization and a third experienced respiratory infections, rates the authors note are comparable to other ALS cohorts. Five patients, 27.8 percent, died during follow-up. The researchers are careful to frame these figures as reflections of advanced disease stage in a population that had already exhausted first-line support, rather than as failures of the high-flow strategy itself.

The physiological findings are the study’s technical core. Before starting therapy, patients showed a mean arterial pH of 7.40, a partial pressure of oxygen of 62.7 millimeters of mercury, a carbon dioxide partial pressure of 36.4 millimeters of mercury, and bicarbonate values ranging from 16 to 29 millimoles per liter. After a period on high-flow cannula, pH ticked up slightly to 7.42, oxygen pressure eased to 59.8 millimeters of mercury, carbon dioxide rose to 42.4 millimeters of mercury, and bicarbonate climbed to 27.8 millimoles per liter. None of these shifts reached statistical significance, and paired analyses confirmed wide confidence intervals spanning zero for every parameter. The authors interpret this stability as clinically meaningful: high-flow nasal cannula does not deliver enough inspiratory pressure support to raise tidal volume or reverse chronic hypercapnia the way mask ventilation can, yet in these carefully selected patients it maintained gas exchange without triggering respiratory acidosis or abrupt deterioration from carbon dioxide retention.

Functional trajectories told a starker story. The Barthel Index, a standard measure of independence in daily activities, fell by an average of 23.3 points, from 35.0 at the start of therapy to 11.7 at the final assessment, a highly significant decline driven chiefly by losses in walking and climbing stairs. The Cruz Roja Functional Classification showed the same slope: at baseline, nearly 78 percent of patients were already at Grades 3 or 4 of physical disability, and by final follow-up more than half had progressed to Grade 5, total dependence, while mild mental impairment rose from 22 percent to 39 percent of the group. Intriguingly, respiratory muscle strength did not follow suit. Maximum inspiratory and expiratory pressures remained essentially unchanged, with p-values of 0.97 and 0.76 respectively. This dissociation, the authors argue, underscores that functional decline in ALS is propelled not only by weakening respiratory muscles but by progressive limb weakness, bulbar dysfunction, and global neurological deterioration.

How do these results sit within the broader literature? The authors point to prior work in neuromuscular disease, including a study by Lionello and colleagues, that likewise documented high patient acceptance of high-flow therapy, with comfort, preserved speech and eating, and reduced claustrophobia cited as decisive advantages. One difference stands out: in that earlier study, three patients receiving continuous 24-hour high-flow support experienced treatment failure, whereas no complications directly attributable to the device were documented in the present cohort. The researchers caution that the descriptive design and small sample make this observation far from definitive, but they suggest it may reflect individualized titration of flow and oxygen and the close multidisciplinary follow-up that a dedicated home care program provides.

The study’s limitations are laid out candidly. A retrospective case series of 18 patients cannot establish causal relationships, and the absence of a comparison group prevents any direct judgment of whether high-flow cannula outperforms persisted mask use or invasive ventilation. Follow-up duration varied by patient because assessments relied on the last recorded clinical evaluation, and treatment discontinuation dates were not systematically documented. Baseline blood gases were drawn during routine care rather than a standardized protocol, so the researchers could not consistently determine whether they were obtained during mask ventilation, how much time elapsed before follow-up measurements, or how long patients had used masks before transitioning. These gaps limit the ability to characterize the longitudinal physiological effects of the therapy or to test whether prior mask exposure shaped tolerance.

Even with those caveats, the report matters for a population with few good options. It provides descriptive, real-world evidence that home-based high-flow nasal cannula is feasible in ALS patients who cannot tolerate masks, that it holds gas exchange steady despite limited ventilatory assistance, and that it may do so without device-attributable complications when embedded in structured multidisciplinary home care. The functional decline observed tracks the natural history of the disease rather than the support modality. The authors call for prospective comparative studies to define more precisely where high-flow therapy belongs in the respiratory management of ALS, but for patients facing the choice between an intolerable mask and an invasive tracheostomy, a comfortable nasal interface that buys stability may represent exactly the middle path the field has been looking for.

Subject of Research: Use of high-flow nasal cannula as home respiratory support in ALS patients intolerant to non-invasive ventilation

Article Title: Use of High‐Flow Nasal Cannula in Amyotrophic Lateral Sclerosis Patients Intolerant to Non‐Invasive Ventilation: A Case Series

Article References: Varon‐Vega, F., Franco Parra, C. E., Adame Ochoa, D. F., Uricoechea, N., Tuta‐Quintero, E., & Martinez Ayala, M. C. (2026). Use of High‐Flow Nasal Cannula in Amyotrophic Lateral Sclerosis Patients Intolerant to Non‐Invasive Ventilation: A Case Series. Respirology Case Reports, 14(9), Article e70744. https://doi.org/10.1002/rcr2.70744

Image Credits: AI Generated

DOI: 10.1002/rcr2.70744

Keywords: amyotrophic lateral sclerosis, high-flow nasal cannula, non-invasive ventilation, chronic respiratory failure, home respiratory care, arterial blood gases, ventilatory support, neuromuscular disease, Barthel Index, case series, respiratory muscle strength, bulbar dysfunction